Ranok Biotech

Ranok Biotech is a clinical-stage biopharmaceutical company pioneering a proprietary approach to targeted protein degradation (TPD). The company's core technology, the Chaperone-mediated Autophagy Targeting Chimera (CHAMP) platform, leverages the cellular autophagy pathway to degrade disease-causing proteins. This platform is designed to improve safety and efficacy compared to traditional TPD methods by utilizing chaperones that are often overexpressed in tumors, potentially providing a tumor-selective degradation mechanism. Ranok's lead candidate, RNK05047, is a first-in-class small molecule degrader of BRD4 currently being evaluated in Phase 1/2 clinical trials for advanced solid tumors and lymphomas. The company maintains dual operations in Hangzhou, China, and the Boston area, USA, to support its global development strategy.